Skip to main content

Harvard Bioscience(HBIO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Harvard Bioscience Schedules Second Quarter 2020 Earnings Conference Call for August 5, 2020 at 8:00 AM ET

Globe NewsWire - Mon Jul 20, 2020

HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m. Eastern Time.

You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 4458189.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, go to  http://investor.harvardbioscience.com/ – Events & Presentations. The webcast will be available on the website through August 12, 2020.

Financial information presented on the call, including the earnings release, will be available on the investor relations section of Harvard Bioscience’s website.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and clinical research organizations. With operations in North America and Europe, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Investor Contact
Michael Rossi
Chief Financial Officer
(508) 893-8999
mrossi@harvardbioscience.com 

Primary Logo

Provided Content: Content provided by Globe NewsWire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe